Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYCLOVIR SODIUM vs AMANTADINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acyclovir is a synthetic nucleoside analogue with activity against herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). It is converted to acyclovir monophosphate by viral thymidine kinase, then further phosphorylated to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporates into viral DNA, causing chain termination.
Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.
Treatment of initial and recurrent genital herpes in immunocompetent patients,Treatment of herpes simplex encephalitis,Treatment of neonatal herpes simplex virus infection,Treatment of varicella-zoster (shingles) in immunocompetent and immunocompromised patients,Treatment of mucocutaneous herpes simplex in immunocompromised patients,Prophylaxis of herpes simplex in immunocompromised patients (off-label)
Prophylaxis and treatment of influenza A virus infection,Treatment of Parkinson's disease and drug-induced extrapyramidal symptoms
Dosing is indication-specific. For herpes simplex encephalitis: 10 mg/kg IV every 8 hours for 10–14 days (adults and children ≥12 years) or 20 mg/kg IV every 8 hours (3 months–12 years). For severe genital herpes: 5 mg/kg IV every 8 hours for 5 days. For mucocutaneous HSV in immunocompromised: 5 mg/kg IV every 8 hours for 7–14 days. For varicella zoster in immunocompromised: 10 mg/kg IV every 8 hours for 7 days. For neonatal HSV: 20 mg/kg IV every 8 hours for 14–21 days (disseminated/CNS) or 14 days (skin/eyes/mouth).
For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.
Terminal elimination half-life: 2.5-3.3 hours in adults with normal renal function; up to 20 hours in anuria/end-stage renal disease.
Terminal elimination half-life: 10-14 hours in young adults; up to 34 hours in elderly (due to age-related decline in renal function); prolonged in renal impairment (up to 7 days in anuria).
Acyclovir is primarily excreted unchanged in the urine via glomerular filtration and tubular secretion. Hepatic metabolism is minimal, with less than 15% metabolized to 9-carboxymethoxymethylguanine via alcohol dehydrogenase and aldehyde dehydrogenase.
Amantadine is primarily excreted unchanged in urine via glomerular filtration and tubular secretion. It undergoes minimal hepatic metabolism, with no major cytochrome P450 involvement.
Primarily renal excretion via glomerular filtration and tubular secretion: 62-91% of dose excreted unchanged in urine within 24 hours; minor biliary/fecal elimination (<2%).
Renal: 90% unchanged drug via glomerular filtration and tubular secretion; minor fecal (<5%) and biliary elimination.
9-33% bound primarily to albumin.
Approximately 67% bound to plasma proteins (mainly albumin).
0.6-1.0 L/kg; approximates total body water, indicating wide distribution including into vesicles and CSF (CSF concentrations ~50% of plasma).
3-10 L/kg, indicating extensive tissue distribution (e.g., brain, lungs, erythrocytes).
Oral: 10-20% (dose-dependent, saturable absorption); topical: negligible systemic absorption.
Oral bioavailability: 86-90% after immediate-release formulation; steady-state achieved within 4-7 days.
Adjust dosing interval based on creatinine clearance (Cr Cl): Cr Cl >50 m L/min: standard dose every 8 hours. Cr Cl 25–50 m L/min: standard dose every 12 hours. Cr Cl 10–25 m L/min: standard dose every 24 hours. Cr Cl 0–10 m L/min: reduce dose by 50% and administer every 24 hours. Hemodialysis: administer after dialysis; typically 50% of standard dose every 24 hours, with a supplemental dose post-dialysis.
Cr Cl 30-50 m L/min: 200 mg on day 1, then 100 mg once daily. Cr Cl 15-29 m L/min: 200 mg on day 1, then 100 mg every other day. Cr Cl <15 m L/min or on hemodialysis: 200 mg every 7 days. Adjust based on clinical response and tolerability.
No dosage adjustment required in isolated hepatic impairment; caution if concomitant renal dysfunction.
No specific dosage adjustment required in hepatic impairment, but use with caution due to potential central nervous system effects.
Indicated in neonates and children. Neonates: 20 mg/kg/dose IV every 8 hours. Infants >3 months: 10–20 mg/kg/dose every 8 hours based on indication. For HSV encephalitis: children 3 months–12 years: 20 mg/kg/dose every 8 hours; ≥12 years: 10 mg/kg/dose every 8 hours. Doses are based on ideal body weight in obese patients.
Influenza A treatment/prophylaxis: children 1-9 years: 4.4-8.8 mg/kg/day (max 150 mg/day) in 1-2 divided doses; 9-12 years: 100 mg twice daily; ≥12 years: adult dosing. Not routinely recommended due to widespread resistance.
No age-specific dose adjustment; dose adjustments are based on renal function, which is often reduced in the elderly. Monitor renal function closely and consider risk of neurotoxic side effects.
Initiate at 100 mg once daily or lower, considering age-related decline in renal function; titrate slowly with careful monitoring for adverse CNS effects.
None.
None
Renal impairment: Dose adjustment required in patients with decreased renal function.,Neurotoxicity: May cause tremors, seizures, hallucinations, or confusion, particularly in elderly patients or those with renal impairment.,Hydration: Ensure adequate hydration during administration to prevent renal tubule crystallization.,Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) reported in immunocompromised patients.,Do not administer by intramuscular or subcutaneous injection due to tissue irritation.
Risk of suicidality, especially in patients with a history of psychiatric disorders,May exacerbate seizure disorder; use with caution in epilepsy,Can cause orthostatic hypotension, dizziness, and blurred vision, impairing ability to drive or operate machinery,Neuroleptic malignant syndrome (NMS) has been reported with dose reduction or discontinuation,Renal function impairment requires dose adjustment; accumulation can cause toxicity,Elderly patients are more susceptible to CNS effects
Hypersensitivity to acyclovir or valacyclovir
Hypersensitivity to amantadine or any component of the formulation,Severe uncontrolled psychiatric disorder (relative)
No significant food interactions. Maintain adequate fluid intake to prevent renal precipitation.
Avoid alcohol and caffeine; alcohol may increase CNS depression, caffeine may exacerbate insomnia and nervousness. No specific food restrictions.
Pregnancy Category B. No evidence of teratogenicity in humans; fetal risks not established in first trimester. Use during pregnancy only if clearly needed.
First trimester: Human data limited; animal studies (rat, rabbit) at doses 2-3 times human therapeutic dose showed increased fetal malformations (cardiovascular, skeletal). Second and third trimesters: No controlled data; case reports of preeclampsia, premature labor, and fetal distress with use near term. FDA Pregnancy Category C.
Acyclovir is excreted in breast milk; M/P ratio 0.6-4.1. Typically compatible with breastfeeding; monitor infant for rash or gastrointestinal disturbances.
Amantadine is excreted into breast milk; milk-to-plasma ratio (M/P) approximately 0.7-1.0 (based on single case, M/P 1.0 at 200 mg/day). Infant serum concentrations up to 6% of maternal therapeutic levels reported. Potential for anticholinergic effects and extrapyramidal symptoms in nursing infant. AAP recommends caution; weight benefits vs. risks.
No routine dose adjustment; pharmacokinetic changes in pregnancy may require increased dosing due to increased clearance and volume of distribution, especially in third trimester. Monitor clinical response.
Pregnancy increases renal clearance (by 20-50% in second/third trimester) due to increased glomerular filtration rate. For Parkinson's disease or influenza A, consider starting at lower dose (100 mg daily) and titrate upward as needed, monitoring for efficacy and CNS side effects. No standard dose adjustment guidelines; individualize based on therapeutic response and tolerance.
Monitor renal function closely; adjust dose in renal impairment. Ensure adequate hydration to prevent crystalluria. Infuse over at least 1 hour to avoid phlebitis. Use with caution in elderly and those with pre-existing renal disease. Neurotoxicity may occur at high doses or in renal failure. Not effective for EBV or CMV treatment.
For Parkinson's disease, start at 100 mg twice daily; increase gradually to 100 mg TID or QID if needed. In elderly or renal impairment, reduce dose. Avoid abrupt discontinuation to prevent neuroleptic malignant syndrome. Monitor for orthostatic hypotension, livedo reticularis, and peripheral edema. Can worsen psychosis in patients with dementia. For influenza A, start within 48 hours of symptoms; not a substitute for vaccination. Use with caution in patients with seizure disorders or heart failure.
Drink plenty of water during treatment to prevent kidney problems.,Report any signs of kidney issues like decreased urine output or swelling.,Notify healthcare provider if you experience confusion, hallucinations, or seizures.,This medication is for intravenous use only and will be given in a medical setting.,Inform your doctor about all medications you are taking, especially other nephrotoxic drugs.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,May cause dizziness or blurred vision; avoid driving until you know how this medicine affects you.,Avoid alcohol as it may increase side effects like dizziness.,Notify your doctor if you experience swelling in your legs or ankles, a lacy purple skin rash, or confusion.,If you miss a dose, take it as soon as you remember unless it is close to your next dose; do not double up.,Wear sunscreen and protective clothing; amantadine may make your skin more sensitive to sunlight.,Do not take this medicine for influenza unless directed by a doctor; it is not a substitute for the flu vaccine.
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
"Concurrent administration of naloxegol, a peripherally-acting mu-opioid receptor antagonist, may increase the serum concentration of amantadine, a weak NMDA receptor antagonist and antiviral agent. This interaction is proposed to occur via competitive inhibition of renal tubular secretion mediated by organic cation transporters (OCTs) present in the proximal tubule, leading to reduced amantadine clearance. Clinically, elevated amantadine levels can precipitate dose-related adverse effects including confusion, hallucinations, orthostatic hypotension, and peripheral edema, particularly in elderly patients or those with pre-existing renal impairment."
"Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor with dose-dependent QT interval prolongation risk due to inhibition of the hERG potassium channel. Amantadine, a dopamine agonist and antiviral agent, also has mild QTc-prolonging properties, possibly through direct myocardial ion channel effects. Concomitant use may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYCLOVIR SODIUM vs AMANTADINE HYDROCHLORIDE, answered by our medical review team.
ACYCLOVIR SODIUM is a Antiviral that works by Acyclovir is a synthetic nucleoside analogue with activity against herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). It is converted to acyclovir monophosphate by viral thymidine kinase, then further phosphorylated to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporates into viral DNA, causing chain termination.. AMANTADINE HYDROCHLORIDE is a Antiviral / Antiparkinsonian that works by Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYCLOVIR SODIUM and AMANTADINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYCLOVIR SODIUM is: Dosing is indication-specific. For herpes simplex encephalitis: 10 mg/kg IV every 8 hours for 10–14 days (adults and children ≥12 years) or 20 mg/kg IV every 8 hours (3 months–12 years). For severe genital herpes: 5 mg/kg IV every 8 hours for 5 days. For mucocutaneous HSV in immunocompromised: 5 mg/kg IV every 8 hours for 7–14 days. For varicella zoster in immunocompromised: 10 mg/kg IV every 8 hours for 7 days. For neonatal HSV: 20 mg/kg IV every 8 hours for 14–21 days (disseminated/CNS) or 14 days (skin/eyes/mouth).. The standard adult dose of AMANTADINE HYDROCHLORIDE is: For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYCLOVIR SODIUM and AMANTADINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYCLOVIR SODIUM is classified as Category A/B. Pregnancy Category B. No evidence of teratogenicity in humans; fetal risks not established in first trimester. Use during pregnancy only if clearly needed.. AMANTADINE HYDROCHLORIDE is classified as Category C. First trimester: Human data limited; animal studies (rat, rabbit) at doses 2-3 times human therapeutic dose showed increased fetal malformations (cardiovascular, skeletal). Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.